vs
Side-by-side financial comparison of COLONY BANKCORP INC (CBAN) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
COLONY BANKCORP INC is the larger business by last-quarter revenue ($39.9M vs $37.2M, roughly 1.1× Organogenesis Holdings Inc.). Over the past eight quarters, COLONY BANKCORP INC's revenue compounded faster (19.6% CAGR vs -46.5%).
Colony Bankcorp Inc is a US-based bank holding company that operates Colony Bank. It provides a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving retail customers and small-to-medium enterprises across the state of Georgia.
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
CBAN vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $37.2M |
| Net Profit | $8.2M | — |
| Gross Margin | — | 30.8% |
| Operating Margin | — | -185.1% |
| Net Margin | 20.6% | — |
| Revenue YoY | — | -57.1% |
| Net Profit YoY | 24.1% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $39.9M | $37.2M | ||
| Q4 25 | $36.9M | $225.6M | ||
| Q3 25 | $32.8M | $150.9M | ||
| Q2 25 | $32.5M | $101.0M | ||
| Q1 25 | $30.0M | $86.7M | ||
| Q4 24 | $30.8M | $126.7M | ||
| Q3 24 | $28.6M | $115.2M | ||
| Q2 24 | $27.9M | $130.2M |
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | $5.8M | $21.6M | ||
| Q2 25 | $8.0M | $-9.4M | ||
| Q1 25 | $6.6M | $-18.8M | ||
| Q4 24 | — | $7.7M | ||
| Q3 24 | $5.6M | $12.3M | ||
| Q2 24 | $5.5M | $-17.0M |
| Q1 26 | — | 30.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 72.6% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 76.7% | ||
| Q2 24 | — | 77.6% |
| Q1 26 | — | -185.1% | ||
| Q4 25 | 25.9% | 28.1% | ||
| Q3 25 | 22.2% | 13.7% | ||
| Q2 25 | 30.9% | -12.5% | ||
| Q1 25 | 27.6% | -30.9% | ||
| Q4 24 | 28.8% | 8.1% | ||
| Q3 24 | 24.6% | 5.4% | ||
| Q2 24 | 24.8% | -10.7% |
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | 19.4% | ||
| Q3 25 | 17.7% | 14.3% | ||
| Q2 25 | 24.6% | -9.3% | ||
| Q1 25 | 22.0% | -21.7% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | 19.7% | 10.7% | ||
| Q2 24 | 19.6% | -13.1% |
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $0.31 | ||
| Q3 25 | $0.33 | $0.11 | ||
| Q2 25 | $0.46 | $-0.10 | ||
| Q1 25 | $0.38 | $-0.17 | ||
| Q4 24 | $0.43 | $0.05 | ||
| Q3 24 | $0.32 | $0.09 | ||
| Q2 24 | $0.31 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $295.8M | $91.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $380.4M | — |
| Total Assets | $3.7B | $520.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $295.8M | $91.4M | ||
| Q4 25 | — | $93.7M | ||
| Q3 25 | — | $63.7M | ||
| Q2 25 | — | $73.1M | ||
| Q1 25 | — | $110.0M | ||
| Q4 24 | — | $135.6M | ||
| Q3 24 | — | $94.3M | ||
| Q2 24 | — | $89.9M |
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $248.0M | — | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $63.8M |
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $300.1M | ||
| Q3 25 | $302.3M | $255.1M | ||
| Q2 25 | $293.9M | $233.2M | ||
| Q1 25 | $286.9M | $242.9M | ||
| Q4 24 | $278.7M | $262.9M | ||
| Q3 24 | $276.1M | $278.5M | ||
| Q2 24 | $264.7M | $263.5M |
| Q1 26 | $3.7B | $520.0M | ||
| Q4 25 | $3.7B | $598.7M | ||
| Q3 25 | $3.2B | $509.8M | ||
| Q2 25 | $3.1B | $461.1M | ||
| Q1 25 | $3.2B | $467.4M | ||
| Q4 24 | $3.1B | $497.9M | ||
| Q3 24 | $3.1B | $446.3M | ||
| Q2 24 | $3.0B | $443.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
ORGO
Segment breakdown not available.
